Indications › Cardiovascular disease › semaglutide

semaglutide in cardiovascular disease

semaglutide is approved in the US for cardiovascular disease, and has 22 trials on file here in this condition. 18 of them are phase 3 or later. The next scheduled result is 2026-12-31.

22 registered trials study semaglutide (Ozempic, Rybelsus, Wegovy) in cardiovascular disease, 16 of them still active and 8 in phase 3. The next is due to report 2026-12-31.

Trials on file: 22
Active: 16
Active phase 3: 8
Participants in active trials: 19,491
Sponsors: 21
Scheduled readouts: 8

Scheduled to report

Dates are filed by the sponsor and move often. Each links to its own record and change history.

Est. completion	Trial	Phase	Participants
2026-12-31	Assessing Incretin Therapy for Cardiovascular Risk Reduction and Diabetes Remission( ITCRDR Study) NCT06959784 · China-Japan Friendship Hospital	P4	142
2027-01	Epicardial Cardiac Fat-CT (EPIC-CT) NCT07297589 · Instituto Mexicano del Seguro Social	P3	136
2027-04	DECODE - Haemodynamic Effects Of Semaglutide and Tirzepatide - a Series of Pilot Studies NCT07483801 · Cambridge University Hospitals NHS Foundation Trust	P4	112
2027-07-31	Efficacy of Semaglutide in Improving Neurological Outcomes After Endovascular Thrombectomy for Acute Ischemic Stroke: A Randomized Double-Blind Controlled Trial NCT07030621 · RenJi Hospital	P3	436
2027-09-01	REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels NCT05669755 · Novo Nordisk A/S	P3	7,101
2028-02	Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke After Endovascular Treatment NCT06788626 · Wei Hu	P3	390
2028-10-31	Glucagon-like Peptide-1 Receptor Agonists for Endovascular Stroke Thrombectomy NCT07511543 · Population Health Research Institute	P2	100
2029-01-01	Screening and Intervention for Subclinical Coronary Artery Disease in Patients With Type 2 Diabetes NCT05700877 · Per Løgstrup Poulsen	P4	7,300

All trials on file

Every registered trial of semaglutide grouped under cardiovascular disease, largest first. Grouping follows the registry’s own condition wording.

Trial	Status	Phase	Sponsor
Screening and Intervention for Subclinical Coronary Artery Disease in Patients With Type 2 Diabetes NCT05700877	Recruiting	P4	Per Løgstrup Poulsen
REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels NCT05669755	Active, not recruiting	P3	Novo Nordisk A/S
Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 Diabetes NCT06082063	Recruiting	P3	Steno Diabetes Center Copenhagen
Efficacy and Safety of Semaglutide Versus Placebo on Cardiometabolic Profile in Patients With Schizophrenia With Metabolic Syndrome NCT07770282	Not yet recruiting	P3	All India Institute of Medical Sciences, Bhubaneswar
Efficacy of Semaglutide in Improving Neurological Outcomes After Endovascular Thrombectomy for Acute Ischemic Stroke: A Randomized Double-Blind Controlled Trial NCT07030621	Not yet recruiting	P3	RenJi Hospital
Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke After Endovascular Treatment NCT06788626	Not yet recruiting	P3	Wei Hu
Acute Subcutaneous SemaglutidE in Acute Ischemic sTroke NCT05630586	Recruiting	P2	Aarhus University Hospital
Anti-atherosclerotic Efficacy of Selected Antidiabetic Drugs in Patients With Coronary Artery Disease and Pre-diabetes NCT07254572	Recruiting	P4	National Institute of Cardiology, Warsaw, Poland
GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV NCT07221214	Recruiting	P2	Vanderbilt University Medical Center
Focusing on the Menopausal Transition to Improve Mid-Life Women's Health NCT06975111	Recruiting	P2/P3	University of Colorado, Denver
Assessing Incretin Therapy for Cardiovascular Risk Reduction and Diabetes Remission( ITCRDR Study) NCT06959784	Enrolling by invitation	P4	China-Japan Friendship Hospital
The POST-ACS Study NCT05322200	Unknown	P4	Swansea Bay University Health Board
Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke Treated by Reperfusion Therapies NCT05920889	Completed	P2	Chinese University of Hong Kong
Semaglutide Treatment On Coronary Progression NCT03985384	Completed	P4	Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Epicardial Cardiac Fat-CT (EPIC-CT) NCT07297589	Recruiting	P3	Instituto Mexicano del Seguro Social
Effect Of Semaglutide In Coronary Atheroma Plaque NCT05071417	Unknown	P3	Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León
DECODE - Haemodynamic Effects Of Semaglutide and Tirzepatide - a Series of Pilot Studies NCT07483801	Not yet recruiting	P4	Cambridge University Hospitals NHS Foundation Trust
Semaglutide and Vascular Regeneration NCT05870462	Unknown	P4	Canadian Medical and Surgical Knowledge Translation Research Group
Glucagon-like Peptide-1 Receptor Agonists for Endovascular Stroke Thrombectomy NCT07511543	Not yet recruiting	P2	Population Health Research Institute
Effect of Oral Semaglutide on Epicardial and Pericoronary Adipose Tissues in Type 2 Diabetes After Myocardial Infarction NCT06557811	Unknown	P4	University of Sao Paulo General Hospital
Effects of Semaglutide on Intracranial Blood Flow and Brain-Barrier Permeability in Type-2 Diabetes NCT05780905	Recruiting	P4	University of Washington
Effect of Glp-1 and Antidiabetic sgLT2 Agents for myoCardial infarcTion and Ultrasensitive Inflammatory Surveillance (GALACTUS Trial) NCT07295223	Recruiting	P3	Instituto Mexicano del Seguro Social

See the full record for semaglutide, or every molecule being studied in cardiovascular disease. These are registered trials, nothing more. Most drugs tested in a new condition never get approved for it, and plenty of these will report nothing useful.